Acarbose, an α-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats

Journal of International Medical Research

Volumn 34, Issue 5, 2006, Pages 525-530

  Nakamura, K ^a   Yamagishi, Shoichi ^a   Matsui, T ^a   Yoshida, T ^a   Imaizumi, T ^a   Makino, T ^b   Shimizu, T ^b   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Acarbose; Antidiabetic agent; Atherosclerosis; Cardiovascular disease; Diabetes; Insulin resistance; Monocyte chemoattractant protein 1 (MCP 1); Post prandial hyperglycaemia

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; FRUCTOSE; INSULIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART PROTECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RAT STRAIN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VASCULAR TISSUE;

EID: 33751053996     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400510     Document Type: Article

References (29)

1. Heine RJ, Dekker JM: Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45: 461-475.
2. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924.
3. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 1999; 354: 617-621.
4. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
5. Breuer HW: Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003; 41: 421-440.
6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486-494.
8. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.
9. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
10. Nakamura K, Yamagishi S, Matsui T, Inoue H: Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats. Drugs Exp Clin Res 2005; 31: 155-159.
11. Rollins BJ: Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996; 2: 198-204.
12. Yamagishi S, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M: Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-25100.
13. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, et al: Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005; 183: 301-317.
14. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, et al: Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004; 44: 1812-1818.
15. Hwang IS, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512-516.
16. Yamagishi S, Nakamura K, Jinnouchi Y, Takenaka K, Imaizumi T: Molecular mechanisms for vascular injury in the metabolic syndrome. Drugs Exp Clin Res 2005; 31: 123-129.
17. Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006; 97: 3A-11A.
18. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS: Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990; 136: 1229-1233.
19. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-1127.
20. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
21. Yamagishi S, Imaizumi T: Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299.
22. Frantz S, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H, et al: Repetitive post-prandial hyperglycemia increases cardiac ischemia/ reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J 2005; 19: 591-593.
23. Lakshminarayanan V, Lewallen M, Frangogiannis NG, Evans AJ, Wedin KE, Michael LH, et al: Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001; 159: 1301-1311.
24. Goebeler M, Gillitzer R, Kilian K, Utzel K, Brocker EB, Rapp UR, et al: Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood 2001; 97: 46-55.
25. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 10.1210/jc.2005-1718. Available at: http://jcem.endojournals.org/cgi/rapidpdf/jc.2005-1718v1 (last accessed 15 June 2006).
26. Sanchez-Moreno C, Dashe JF, Scott T, Thaler D, Folstein MF, Martin A: Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004; 35: 163-168.
27. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, et al: Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165: 186S-1874.
28. Yamagishi S, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A, et al: Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004; 37: 497-506.
29. Yamagishi S, Matsui T, Nakamura K, Takeuchi M: Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 2005; 27: 189-195.